Gabapentin GR: Phase III started

Depomed began the double-blind, placebo-controlled Phase III Breeze 1 trial to evaluate 1,200 mg Gabapentin GR given once daily, or 600 mg Gabapentin GR in the morning plus 1,200 mg Gabapentin GR in t...